

Table 2. Hazard Ratios and 95% Confidence Intervals for the Primary, Secondary, and Other End Points, According to Randomized Assignment to n–3 Fatty Acids or Placebo, in Intention-to-Treat Analyses.*

End Point	n–3 Group (N = 12,933) <i>no. of participants with event</i>	Placebo Group (N = 12,938) <i>no. of participants with event</i>	Hazard Ratio (95% CI)
Cardiovascular disease			
Primary end point: major cardiovascular event†	386	419	0.92 (0.80–1.06)
Cardiovascular event in expanded composite end point‡	527	567	0.93 (0.82–1.04)
Myocardial infarction§	145	200	0.72 (0.59–0.90)
Total stroke	148	142	1.04 (0.83–1.31)
Death from cardiovascular causes	142	148	0.96 (0.76–1.21)
Other cardiovascular end point§			
PCI	162	208	0.78 (0.63–0.95)
CABG	85	86	0.99 (0.73–1.33)
Total coronary heart disease¶	308	370	0.83 (0.71–0.97)
Ischemic stroke	111	116	0.96 (0.74–1.24)
Hemorrhagic stroke	25	19	1.32 (0.72–2.39)
Death from coronary heart disease	37	49	0.76 (0.49–1.16)
Death from myocardial infarction	13	26	0.50 (0.26–0.97)
Death from stroke	22	20	1.10 (0.60–2.01)